Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Erleada® (apalutamide) – New indication
September 17, 2019 - Janssen announced the FDA approval of Erleada (apalutamide), for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
